NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CARCINOMA (MORPHEUS-NEO HCC)

This is a research study that is designed to test new drug combinations for treating liver cancer (hepatocellular carcinoma) in people who can have surgery to remove the cancer. The treatments being tested in this study are immunotherapy combinations. Immunotherapy helps the body’s immune system recognize and attack cancer cells. This is an open label, multi-centre and randomized phase 1b/II study.

Open-Label: Patients know which treatments are being given to them

Randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05908786

Clinical Trial Site: Einstein

To see all available clinical trials click here.